[Low doses of subcutaneous cytosine arabinoside in the treatment of patients with myelodysplastic syndromes].
Avilés
A
A
Tripp
F
F
Velásquez
A
A
Rubio
M E
ME
González-Llavén
J
J
D000741:Anemia, Aplastic / Q000139:chemically induced; D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007239:Infections / Q000209:etiology; D007279:Injections, Subcutaneous; D007951:Leukemia, Myeloid / Q000188:drug therapy*
D003561:Cytarabine
Dosis bajas de arabinósido de citosina subcutáneo en el tratamiento de pacientes con síndromes mielodisplásicos.